[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
Curr Opin Virol. 2019 Mar 15;34:140-148. doi: 10.1016/j.coviro.2019.01.003. [Epub ahead of print]
Achieving cross-reactivity with pan-ebolavirus antibodies.
King LB1, Milligan JC1, West BR1, Schendel SL1, Ollmann Saphire E2.
Author information: 1 Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA. 2 Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: firstname.lastname@example.org.
Filoviruses are the causative agents of highly lethal outbreaks in sub-Saharan Africa. Although an experimental vaccine and several therapeutics are being deployed in the Democratic Republic of Congo to combat the ongoing Ebola virus outbreak, these therapies are specific for only one filovirus species. There is currently significant interest in developing broadly reactive monoclonal antibodies (mAbs) with utility against the variety of ebolaviruses that may emerge. Thus far, the primary target of these mAbs has been the viral spike glycoprotein (GP). Here we present an overview of GP-targeted antibodies that exhibit broad reactivity and the structural characteristics that could confer this cross-reactivity. We also discuss how these structural features could be leveraged to design vaccine antigens that elicit cross-reactive antibodies.
Copyright © 2019 Elsevier B.V. All rights reserved.
PMID: 30884329 DOI: 10.1016/j.coviro.2019.01.003
Keywords: Ebola; Filovirus; Monoclonal antibodies.